{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:14:15Z","timestamp":1789398855435,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["174100157"],"award-info":[{"award-number":["174100157"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00392-023-02366-2","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:02:43Z","timestamp":1704290563000},"page":"1211-1218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["GLP-1 in patients with myocardial infarction complicated by cardiogenic shock\u2014an IABP-SHOCK II-substudy"],"prefix":"10.1007","volume":"113","author":[{"given":"Michael","family":"Lehrke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-8772","authenticated-orcid":false,"given":"Georg","family":"Fuernau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kahles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Moellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Eitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Thelemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Desch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Werdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"2366_CR1","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/eurheartj\/ehz363","volume":"40","author":"H Thiele","year":"2019","unstructured":"Thiele H, Ohman EM, de Waha-Thiele S et al (2019) Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J 40:2671\u20132683. https:\/\/doi.org\/10.1093\/eurheartj\/ehz363","journal-title":"Eur Heart J"},{"key":"2366_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/01.ta.0000197374.99755.fe","volume":"60","author":"K Shimizu","year":"2006","unstructured":"Shimizu K, Ogura H, Goto M et al (2006) Altered gut flora and environment in patients with severe SIRS. J Trauma 60:126\u2013133. https:\/\/doi.org\/10.1097\/01.ta.0000197374.99755.fe","journal-title":"J Trauma"},{"key":"2366_CR3","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131\u20132157. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.054","journal-title":"Gastroenterology"},{"key":"2366_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ (2016) The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab 24:15\u201330. https:\/\/doi.org\/10.1016\/j.cmet.2016.06.009","journal-title":"Cell Metab"},{"key":"2366_CR5","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1111\/dom.13472","volume":"20","author":"S Diebold","year":"2018","unstructured":"Diebold S, Moellmann J, Kahles F et al (2018) Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity. Diabetes Obes Metab 20:2911\u20132918. https:\/\/doi.org\/10.1111\/dom.13472","journal-title":"Diabetes Obes Metab"},{"key":"2366_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/eurheartj\/ehz728","volume":"41","author":"F Kahles","year":"2020","unstructured":"Kahles F, Ruckbeil MV, Mertens RW et al (2020) Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. Eur Heart J 41:882\u2013889. https:\/\/doi.org\/10.1093\/eurheartj\/ehz728","journal-title":"Eur Heart J"},{"key":"2366_CR7","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ahj.2012.03.012","volume":"163","author":"H Thiele","year":"2012","unstructured":"Thiele H, Schuler G, Neumann FJ et al (2012) Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 163:938\u2013945. https:\/\/doi.org\/10.1016\/j.ahj.2012.03.012","journal-title":"Am Heart J"},{"key":"2366_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367","author":"H Thiele","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann FJ et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. NEnglJMed 367:1287\u20131296. https:\/\/doi.org\/10.1056\/NEJMoa1208410","journal-title":"NEnglJMed"},{"key":"2366_CR9","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(13)61783-3","volume":"382","author":"H Thiele","year":"2013","unstructured":"Thiele H, Zeymer U, Neumann FJ et al (2013) Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 382:1638\u20131645. https:\/\/doi.org\/10.1016\/S0140-6736(13)61783-3","journal-title":"Lancet"},{"key":"2366_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIRCULATIONAHA.118.038201","volume":"139","author":"H Thiele","year":"2019","unstructured":"Thiele H, Zeymer U, Thelemann N et al (2019) Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction. Circulation 139:395\u2013403. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038201","journal-title":"Circulation"},{"key":"2366_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/ejhf.117","volume":"16","author":"G Fuernau","year":"2014","unstructured":"Fuernau G, Poenisch C, Eitel I et al (2014) Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial. Eur J Heart Fail 16:880\u2013887. https:\/\/doi.org\/10.1002\/ejhf.117","journal-title":"Eur J Heart Fail"},{"key":"2366_CR12","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.2337\/db14-0100","volume":"63","author":"F Kahles","year":"2014","unstructured":"Kahles F, Meyer C, Mollmann J et al (2014) GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63:3221\u20133229. https:\/\/doi.org\/10.2337\/db14-0100","journal-title":"Diabetes"},{"key":"2366_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12933-016-0330-8","volume":"15","author":"C Lebherz","year":"2016","unstructured":"Lebherz C, Kahles F, Piotrowski K et al (2016) Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism. Cardiovasc Diabetol 15:21. https:\/\/doi.org\/10.1186\/s12933-016-0330-8","journal-title":"Cardiovasc Diabetol"},{"issue":"833\u201341","key":"2366_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.03.010","volume":"130","author":"C Lebherz","year":"2017","unstructured":"Lebherz C, Schlieper G, Mollmann J et al (2017) GLP-1 levels predict mortality in patients with critical illness as well as end-stage renal disease. Am J Med 130(833\u201341):e3. https:\/\/doi.org\/10.1016\/j.amjmed.2017.03.010","journal-title":"Am J Med"},{"key":"2366_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","volume":"110","author":"S Steven","year":"2015","unstructured":"Steven S, Hausding M, Kroller-Schon S et al (2015) Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res Cardiol 110:6. https:\/\/doi.org\/10.1007\/s00395-015-0465-x","journal-title":"Basic Res Cardiol"},{"key":"2366_CR16","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","volume":"41","author":"F Marsico","year":"2020","unstructured":"Marsico F, Paolillo S, Gargiulo P et al (2020) Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J 41:3346\u20133358. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa082","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02366-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02366-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02366-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T18:18:57Z","timestamp":1721845137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02366-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02366-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"3 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ML received grants and personal fees from Boehringer Ingelheim, grants and personal fees from MSD, grants and personal fees from Novo Nordisk, personal fees from Amgen, personal fees from Sanofi, personal fees from Astra Zeneca, personal fees from Bayer, personal fees from Lilly. FK has served as a speaker for Novo Nordisk, JM declares no conflict of interest, NM has served as speaker for Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk. All other authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}